

Giuseppe Giannini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/810672/publications.pdf>

Version: 2024-02-01

151
papers

9,458
citations

57758

44
h-index

40979

93
g-index

156
all docs

156
docs citations

156
times ranked

15724
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 4459-4464.	7.1	878
2	The CREB Coactivator TORC2 Functions as a Calcium- and cAMP-Sensitive Coincidence Detector. Cell, 2004, 119, 61-74.	28.9	581
3	TORCs. Molecular Cell, 2003, 12, 413-423.	9.7	564
4	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
5	cAMP promotes pancreatic Î²-cell survival via CREB-mediated induction of IRS2. Genes and Development, 2003, 17, 1575-1580.	5.9	491
6	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
7	Histone deacetylase and Cullin3-RING1 ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nature Cell Biology, 2010, 12, 132-142.	10.3	292
8	Thyroxine in Goiter, <i>Helicobacter pylori</i> Infection, and Chronic Gastritis. New England Journal of Medicine, 2006, 354, 1787-1795.	27.0	284
9	Numb is a suppressor of Hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nature Cell Biology, 2006, 8, 1415-1423.	10.3	259
10	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
11	Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO Journal, 2010, 29, 2646-2658.	7.8	208
12	Attenuation of a phosphorylation-dependent activator by an HDAC-PP1 complex. Nature Structural and Molecular Biology, 2003, 10, 175-181.	8.2	179
13	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. EBioMedicine, 2017, 20, 39-49.	6.1	170
14	Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Reports, 2002, 3, 248-254.	4.5	169
15	Mir-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastoma cell motility and invasiveness. FASEB Journal, 2009, 23, 4276-4287.	0.5	148
16	Gli1/ <sc>DNA</sc> interaction is a druggable target for Hedgehog-dependent tumors. EMBO Journal, 2015, 34, 200-217.	7.8	147
17	The role of peroxiredoxins in cancer. Molecular and Clinical Oncology, 2017, 6, 139-153.	1.0	145
18	Mutations of an intronic repeat induce impaired MRE11 expression in primary human cancer with microsatellite instability. Oncogene, 2004, 23, 2640-2647.	5.9	101

#	ARTICLE	IF	CITATIONS
19	Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. <i>Nature Genetics</i> , 2012, 44, 1182-1184.	21.4	99
20	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
21	Identification and Characterization of KCASH2 and KCASH3, 2 Novel Cullin3 Adaptors Suppressing Histone Deacetylase and Hedgehog Activity in Medulloblastoma. <i>Neoplasia</i> , 2011, 13, 374-IN23.	5.3	82
22	Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma. <i>Cancer Cell</i> , 2017, 31, 50-63.	16.8	79
23	Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 411-418.	2.5	73
24	microRNA-17-92 cluster is a direct Nanog target and controls neural stem cell through Trp53inp1. <i>EMBO Journal</i> , 2013, 32, 2819-2832.	7.8	70
25	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	2.9	68
26	EGF and cell cycle regulated <i>STAG1</i> / <i>PMEPA1</i> / <i>ERG1.2</i> belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer. <i>Molecular Carcinogenesis</i> , 2003, 38, 188-200.	2.7	66
27	Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. <i>Cell Metabolism</i> , 2005, 2, 331-338.	16.2	65
28	NF- κ B, and not MYCN, Regulates MHC Class I and Endoplasmic Reticulum Aminopeptidases in Human Neuroblastoma Cells. <i>Cancer Research</i> , 2010, 70, 916-924.	0.9	65
29	Non-canonical Hedgehog/AMPK-Mediated Control of Polyamine Metabolism Supports Neuronal and Medulloblastoma Cell Growth. <i>Developmental Cell</i> , 2015, 35, 21-35.	7.0	62
30	β -arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells. <i>BMC Cancer</i> , 2017, 17, 488.	2.6	62
31	Gli2 Acetylation at Lysine 757 Regulates Hedgehog-Dependent Transcriptional Output by Preventing Its Promoter Occupancy. <i>PLoS ONE</i> , 2013, 8, e65718.	2.5	61
32	The coactivator CRTC1 promotes cell proliferation and transformation via AP-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 1445-1450.	7.1	59
33	Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. <i>Scientific Reports</i> , 2018, 8, 3702.	3.3	59
34	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2014, 16, 3416.	5.0	57
35	Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma. <i>Scientific Reports</i> , 2017, 7, 44079.	3.3	57
36	BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 57, 1-23.	4.4	54

#	ARTICLE	IF	CITATIONS
37	BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 577-586.	2.5	53
38	Itch/ β 2-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. <i>Nature Communications</i> , 2018, 9, 976.	12.8	53
39	High Mobility Group A1 Is a Molecular Target for MYCN in Human Neuroblastoma. <i>Cancer Research</i> , 2005, 65, 8308-8316.	0.9	50
40	Molecular structure and tissue distribution of ryanodine receptors calcium channels. <i>Medicinal Research Reviews</i> , 1995, 15, 313-323.	10.5	49
41	Inhibition of Hedgehog-dependent tumors and cancer stem cells by a newly identified naturally occurring chemotype. <i>Cell Death and Disease</i> , 2016, 7, e2376-e2376.	6.3	49
42	Activation of Three Distinct RXR/RAR Heterodimers Induces Growth Arrest and Differentiation of Neuroblastoma Cells. <i>Journal of Biological Chemistry</i> , 1997, 272, 26693-26701.	3.4	48
43	An Integrated Approach Identifies Nhlh1 and Insm1 as Sonic Hedgehog-regulated Genes in Developing Cerebellum and Medulloblastoma. <i>Neoplasia</i> , 2008, 10, 89-103.	5.3	48
44	Common Variants at the 19p13.1 and <i>ZNF365</i> Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 645-657.	2.5	47
45	Hedgehog/Gli Control by Ubiquitination/Acetylation Interplay. <i>Vitamins and Hormones</i> , 2012, 88, 211-227.	1.7	47
46	MRE11 expression is impaired in gastric cancer with microsatellite instability. <i>Carcinogenesis</i> , 2004, 25, 2337-2343.	2.8	46
47	The RNA-Binding Ubiquitin Ligase MEX3A Affects Glioblastoma Tumorigenesis by Inducing Ubiquitylation and Degradation of RIG-I. <i>Cancers</i> , 2020, 12, 321.	3.7	46
48	Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome. <i>DNA Repair</i> , 2003, 2, 547-559.	2.8	45
49	Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38 β modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A. <i>Cancer Letters</i> , 2014, 344, 110-118.	7.2	45
50	PALB2 mutations in male breast cancer: a population-based study in Central Italy. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 299-301.	2.5	44
51	Druggable glycolytic requirement for Hedgehog-dependent neuronal and medulloblastoma growth. <i>Cell Cycle</i> , 2014, 13, 3404-3413.	2.6	44
52	Digging a hole under Hedgehog: downstream inhibition as an emerging anticancer strategy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 62-72.	7.4	44
53	Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 42.	3.7	44
54	The growth arrest and downregulation of c-myc transcription induced by ceramide are related events dependent on p21 induction, Rb underphosphorylation and E2F sequestering. <i>Cell Death and Differentiation</i> , 1998, 5, 381-389.	11.2	43

#	ARTICLE	IF	CITATIONS
55	BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 161-167.	2.5	42
56	cDNA cloning reveals a tissue specific expression of alternatively spliced transcripts of the ryanodine receptor type 3 (RyR3) calcium release channel. <i>FEBS Letters</i> , 1996, 394, 76-82.	2.8	41
57	Circulating tumor cells. <i>Cancer Biology and Therapy</i> , 2014, 15, 496-503.	3.4	40
58	Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. <i>International Journal of Cancer</i> , 2019, 145, 390-400.	5.1	40
59	The energy sensor AMPK regulates Hedgehog signaling in human cells through a unique Gli1 metabolic checkpoint. <i>Oncotarget</i> , 2016, 7, 9538-9549.	1.8	40
60	Obinutuzumab-mediated high-affinity ligation of Fc γ RIIIA/CD16 primes NK cells for IFN γ production. <i>Oncolmmunology</i> , 2017, 6, e1290037.	4.6	39
61	Targeting class I histone deacetylases by the novel small molecule inhibitor 4-SC β 2 blocks oncogenic hedgehog β signaling and overcomes smoothed inhibitor resistance. <i>International Journal of Cancer</i> , 2018, 142, 968-975.	5.1	39
62	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.9	39
63	Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation. <i>Cell Death and Disease</i> , 2020, 11, 1045.	6.3	39
64	Genomic characterization of the coding region of the human type II 5 α -deiodinase gene. <i>Molecular and Cellular Endocrinology</i> , 1998, 141, 49-52.	3.2	37
65	Phenformin Inhibits Hedgehog-Dependent Tumor Growth through a Complex I-Independent Redox/Corepressor Module. <i>Cell Reports</i> , 2020, 30, 1735-1752.e7.	6.4	37
66	MRE11 inhibition highlights a replication stress-dependent vulnerability of MYCN-driven tumors. <i>Cell Death and Disease</i> , 2018, 9, 895.	6.3	35
67	ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of β TrCP. <i>Nature Communications</i> , 2019, 10, 3304.	12.8	35
68	Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2011, 1815, 241-252.	7.4	32
69	Nanotechnology-Based Strategies to Develop New Anticancer Therapies. <i>Biomolecules</i> , 2020, 10, 735.	4.0	32
70	Whole β ome sequencing and targeted gene sequencing provide insights into the role of <i>PALB2</i> as a male breast cancer susceptibility gene. <i>Cancer</i> , 2017, 123, 210-218.	4.1	31
71	MYCN Sensitizes Human Neuroblastoma to Apoptosis by HIPK2 Activation through a DNA Damage Response. <i>Molecular Cancer Research</i> , 2011, 9, 67-77.	3.4	30
72	Validation of the Ion Torrent PGM sequencing for the prospective routine molecular diagnostic of colorectal cancer. <i>Clinical Biochemistry</i> , 2015, 48, 908-910.	1.9	30

#	ARTICLE	IF	CITATIONS
73	Molecular mechanism of HMGA1 deregulation in human neuroblastoma. <i>Cancer Letters</i> , 2005, 228, 97-104.	7.2	29
74	Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup. <i>Biomarker Research</i> , 2015, 3, 13.	6.8	28
75	Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families. <i>Cancer Medicine</i> , 2018, 7, 46-55.	2.8	28
76	Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2007, 106, 289-296.	2.5	27
77	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 671-679.	2.5	27
78	PRDX1 and PRDX6 are repressed in papillary thyroid carcinomas via BRAF V600E-dependent and -independent mechanisms. <i>International Journal of Oncology</i> , 2014, 44, 548-556.	3.3	27
79	Novel and known genetic variants for male breast cancer risk at 8q24.21, 9p21.3, 11q13.3 and 14q24.1: Results from a multicenter study in Italy. <i>European Journal of Cancer</i> , 2015, 51, 2289-2295.	2.8	25
80	Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer. <i>Cancer Biology and Therapy</i> , 2014, 15, 826-831.	3.4	24
81	Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. <i>Cancer Research</i> , 2019, 79, 5575-5586.	0.9	24
82	Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells. <i>PLoS ONE</i> , 2012, 7, e49139.	2.5	22
83	The HMGA1 protooncogene frequently deregulated in cancer is a transcriptional target of E2F1. <i>Molecular Carcinogenesis</i> , 2013, 52, 526-534.	2.7	22
84	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	2.5	22
85	Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 83-91.	2.5	21
86	KCTD15 inhibits the Hedgehog pathway in Medulloblastoma cells by increasing protein levels of the oncosuppressor KCASH2. <i>Oncogenesis</i> , 2019, 8, 64.	4.9	21
87	Next-generation sequencing of <i>BRCA1</i> and <i>BRCA2</i> genes for rapid detection of germline mutations in hereditary breast/ovarian cancer. <i>PeerJ</i> , 2019, 7, e6661.	2.0	21
88	MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells. <i>PLoS ONE</i> , 2015, 10, e0143333.	2.5	21
89	Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achilles' heel to be exploited for the therapy of MYCN-amplified neuroblastoma. <i>Frontiers in Oncology</i> , 2012, 2, 141.	2.8	20
90	Functional characterisation of the CRE/TATA box unit of type 2 deiodinase gene promoter in a human choriocarcinoma cell line. <i>Journal of Molecular Endocrinology</i> , 2004, 33, 51-58.	2.5	19

#	ARTICLE	IF	CITATIONS
91	Mitogen-activated kinase kinase kinase 1 inhibits hedgehog signaling and medulloblastoma growth through GLI1 phosphorylation. <i>International Journal of Oncology</i> , 2019, 54, 505-514.	3.3	19
92	Activation of Thyroid Hormone Is Transcriptionally Regulated by Epidermal Growth Factor in Human Placenta-Derived JEG3 Cells. <i>Endocrinology</i> , 2008, 149, 695-702.	2.8	17
93	CNBP regulates wing development in <i>Drosophila melanogaster</i> by promoting IRES-dependent translation of dMyc. <i>Cell Cycle</i> , 2014, 13, 434-439.	2.6	17
94	Polyamine Metabolism as a Therapeutic Target in Hedgehog-Driven Basal Cell Carcinoma and Medulloblastoma. <i>Cells</i> , 2019, 8, 150.	4.1	17
95	Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software. <i>European Journal of Human Genetics</i> , 2006, 14, 49-54.	2.8	16
96	The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. <i>European Journal of Human Genetics</i> , 2010, 18, 856-858.	2.8	16
97	A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors. <i>Oncogene</i> , 2021, 40, 6143-6152.	5.9	16
98	Thrombospondin-1 Is a Mediator of the Neurotypic Differentiation Induced by EGF in Thymic Epithelial Cells. <i>Experimental Cell Research</i> , 1999, 248, 79-86.	2.6	15
99	New mutations and protein variants of NBS1 are identified in cancer cell lines. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 198-204.	2.8	15
100	Human Papilloma Virus-Dependent HMGA1 Expression Is a Relevant Step in Cervical Carcinogenesis. <i>Neoplasia</i> , 2008, 10, 773-781.	5.3	15
101	Clinical Classification of BRCA1 DNA Missense Variants: H1686Q Is a Novel Pathogenic Mutation Occurring in the Ontogenetically Invariant THV Motif of the N-Terminal BRCT Domain. <i>Journal of Clinical Oncology</i> , 2008, 26, 4212-4214.	1.6	15
102	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 147.	3.7	15
103	The Mechanism of Action of Biguanides: New Answers to a Complex Question. <i>Cancers</i> , 2022, 14, 3220.	3.7	14
104	Yin-Yang strands of PCAF/Hedgehog axis in cancer control. <i>Trends in Molecular Medicine</i> , 2014, 20, 416-418.	6.7	13
105	Translating Hedgehog in Cancer: Controlling Protein Synthesis. <i>Trends in Molecular Medicine</i> , 2016, 22, 851-862.	6.7	13
106	Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition. <i>Molecular and Clinical Oncology</i> , 2018, 9, 30-34.	1.0	13
107	Drug Design and Synthesis of First in Class PDZ1 Targeting NHERF1 Inhibitors as Anticancer Agents. <i>ACS Medicinal Chemistry Letters</i> , 2019, 10, 499-503.	2.8	13
108	Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response. <i>Oncogenesis</i> , 2020, 9, 93.	4.9	13

#	ARTICLE	IF	CITATIONS
109	MUC Gene Abnormalities in Sporadic and Hereditary Mucinous Colon Cancers with Microsatellite Instability. <i>Disease Markers</i> , 2005, 21, 121-126.	1.3	12
110	Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 629-635.	2.5	12
111	Maize polyamine oxidase in the presence of spermine/spermidine induces the apoptosis of LoVo human colon adenocarcinoma cells. <i>International Journal of Oncology</i> , 2019, 54, 2080-2094.	3.3	12
112	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 560.	2.8	12
113	Aged garlic extract and its constituent, S-allyl-L-cysteine, induce the apoptosis of neuroblastoma cancer cells due to mitochondrial membrane depolarization. <i>Experimental and Therapeutic Medicine</i> , 2020, 19, 1511-1521.	1.8	12
114	TORCs/CRTCs: More than mere coincidence. <i>Cell Cycle</i> , 2009, 8, 959-964.	2.6	11
115	The CASP8 rs3834129 polymorphism and breast cancer risk in BRCA1 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 855-860.	2.5	11
116	Pharmacological targeting of the novel β -catenin chromatin-associated kinase p38 β in colorectal cancer stem cell tumorspheres and organoids. <i>Cell Death and Disease</i> , 2021, 12, 316.	6.3	11
117	The antioxidant, aged garlic extract, exerts cytotoxic effects on wild-type and multidrug-resistant human cancer cells by altering mitochondrial permeability. <i>International Journal of Oncology</i> , 2018, 53, 1257-1268.	3.3	10
118	True conversions from RAS mutant to RAS wild-type in circulating tumor DNA from metastatic colorectal cancer patients as assessed by methylation and mutational signature. <i>Cancer Letters</i> , 2021, 507, 89-96.	7.2	10
119	Translational control of polyamine metabolism by CNBP is required for <i>Drosophila</i> locomotor function. <i>ELife</i> , 2021, 10, .	6.0	10
120	HE4 in the Differential Diagnosis of a Pelvic Mass: A Case Report. <i>International Journal of Molecular Sciences</i> , 2011, 12, 627-632.	4.1	9
121	Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 135.	8.6	9
122	A MYCN-MRN complex axis controls replication stress for the safe expansion of neuroprogenitor cells. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1079673.	0.7	9
123	Enzymatic Spermine Metabolites Induce Apoptosis Associated with Increase of p53, caspase-3 and miR-34a in Both Neuroblastoma Cells, SJNKP and the N-Myc-Amplified Form IMR5. <i>Cells</i> , 2021, 10, 1950.	4.1	9
124	Downregulation of miR-326 and its host gene β -arrestin1 induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	4.6	8
125	RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study. <i>Cancers</i> , 2022, 14, 802.	3.7	8
126	Turning off the switch in medulloblastoma: The inhibitory acetylation of an oncogene. <i>Cell Cycle</i> , 2010, 9, 2047-2048.	2.6	7

#	ARTICLE	IF	CITATIONS
127	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. <i>OncoTargets and Therapy</i> , 2013, 6, 1761.	2.0	7
128	Coexistence of three EGFR mutations in an NSCLC patient: A brief report. <i>International Journal of Biological Markers</i> , 2018, 33, 545-548.	1.8	7
129	Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 1414.	2.8	7
130	PIK3CA somatic mutation in sinonasal teratocarcinoma. <i>Auris Nasus Larynx</i> , 2021, 48, 530-534.	1.2	7
131	High plasma levels of endothelin-1 in untreated Addison's disease. <i>European Journal of Endocrinology</i> , 1996, 135, 696-699.	3.7	6
132	2-Aminopurine Unravels a Role for pRB in the Regulation of Gene Expression by Transforming Growth Factor β . <i>Journal of Biological Chemistry</i> , 1997, 272, 5313-5319.	3.4	6
133	EGF Regulates a Complex Pattern of Gene Expression and Represses Smooth Muscle Differentiation during the Neurotypic Conversion of the Neural-Crest-Derived TC-1S Cell Line. <i>Experimental Cell Research</i> , 2001, 264, 353-362.	2.6	6
134	Does the Search for Large Genomic Rearrangements Impact BRCA1 Carrier Prediction?. <i>Journal of Clinical Oncology</i> , 2007, 25, 2632-2634.	1.6	6
135	CCAAT/Enhancer-Binding Proteins Are Key Regulators of Human Type Two Deiodinase Expression in a Placenta Cell Line. <i>Endocrinology</i> , 2012, 153, 4030-4038.	2.8	6
136	Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance. <i>Cancers</i> , 2021, 13, 4515.	3.7	6
137	Evaluation of CYP17A1 and CYP11B1 polymorphisms in male breast cancer risk. <i>Endocrine Connections</i> , 2019, 8, 1224-1229.	1.9	6
138	A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. <i>Leukemia and Lymphoma</i> , 2006, 47, 1421-1423.	1.3	5
139	Sulfonamide Inhibitors of β -Catenin Signaling as Anticancer Agents with Different Output on β -MYC. <i>ChemMedChem</i> , 2020, 15, 2264-2268.	3.2	5
140	A multidisciplinary approach for the differential diagnosis between multiple primary lung adenocarcinomas and intrapulmonary metastases. <i>Pathology Research and Practice</i> , 2021, 220, 153387.	2.3	5
141	Specific Protein 1 and p53 Interplay Modulates the Expression of the KCTD-Containing Cullin3 Adaptor Suppressor of Hedgehog 2. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 638508.	3.7	5
142	Induction of Pro-Fibrotic CLIC4 in Dermal Fibroblasts by TGF- β /Wnt3a Is Mediated by GLI2 Upregulation. <i>Cells</i> , 2022, 11, 530.	4.1	5
143	SMO-M2 mutation does not support cell-autonomous Hedgehog activity in cerebellar granule cell precursors. <i>Scientific Reports</i> , 2019, 9, 19623.	3.3	4
144	Discovery of novel human lactate dehydrogenase inhibitors: Structure-based virtual screening studies and biological assessment. <i>European Journal of Medicinal Chemistry</i> , 2022, 240, 114605.	5.5	4

#	ARTICLE	IF	CITATIONS
145	Determination of Acetylation of the Gli Transcription Factors. <i>Methods in Molecular Biology</i> , 2015, 1322, 147-156.	0.9	3
146	Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments. <i>Diagnostics</i> , 2021, 11, 2196.	2.6	3
147	Identification of novel <i>BRCA1</i> large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data. <i>PeerJ</i> , 2019, 7, e7972.	2.0	2
148	5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	2
149	A novel <i>BRCA2</i> splice variant identified in a young woman. <i>Molecular Genetics & Genomic Medicine</i> , 2020, 8, e1513.	1.2	1
150	Direct Correlation Between Double K-RAS Mutation and Mucinous Carcinoma. A Case Report. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2015, 23, e4-e7.	1.2	0
151	An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy. <i>Biology Direct</i> , 2022, 17, 10.	4.6	0